COVID-19 biomarkers and their overlap with comorbidities in a disease biomarker data model
Crandall, Keith A.
Natale, Darren A.
Schriml, Lynn M.
JournalBriefings in Bioinformatics
PublisherOxford University Press
MetadataShow full item record
AbstractAbstract In response to the COVID-19 outbreak, scientists and medical researchers are capturing a wide range of host responses, symptoms and lingering postrecovery problems within the human population. These variable clinical manifestations suggest differences in influential factors, such as innate and adaptive host immunity, existing or underlying health conditions, comorbidities, genetics and other factors-compounding the complexity of COVID-19 pathobiology and potential biomarkers associated with the disease, as they become available. The heterogeneous data pose challenges for efficient extrapolation of information into clinical applications. We have curated 145 COVID-19 biomarkers by developing a novel cross-cutting disease biomarker data model that allows integration and evaluation of biomarkers in patients with comorbidities. Most biomarkers are related to the immune (SAA, TNF-∝ and IP-10) or coagulation (D-dimer, antithrombin and VWF) cascades, suggesting complex vascular pathobiology of the disease. Furthermore, we observe commonality with established cancer biomarkers (ACE2, IL-6, IL-4 and IL-2) as well as biomarkers for metabolic syndrome and diabetes (CRP, NLR and LDL). We explore these trends as we put forth a COVID-19 biomarker resource (https://data.oncomx.org/covid19) that will help researchers and diagnosticians alike. © The Author(s) 2021.
SponsorsNational Science Foundation
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17641
- COVID-19 Biomarkers in research: Extension of the OncoMX cancer biomarker data model to capture biomarker data from other diseases.
- Authors: Gogate N, Lyman D, Crandall KA, Kahsay R, Natale DA, Sen S, Mazumder R
- Issue date: 2020 Sep 10
- Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19.
- Authors: Ye W, Chen G, Li X, Lan X, Ji C, Hou M, Zhang D, Zeng G, Wang Y, Xu C, Lu W, Cui R, Cai Y, Huang H, Yang L
- Issue date: 2020 Jul 3
- Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
- Authors: Azar MM, Shin JJ, Kang I, Landry M
- Issue date: 2020 Nov
- New Insights in Laboratory Testing for COVID-19 Patients: Looking for the Role and Predictive Value of Human epididymis secretory protein 4 (HE4) and the Innate Immunity of the Oral Cavity and Respiratory Tract.
- Authors: Schirinzi A, Cazzolla AP, Lovero R, Lo Muzio L, Testa NF, Ciavarella D, Palmieri G, Pozzessere P, Procacci V, Di Serio F, Santacroce L
- Issue date: 2020 Nov 2
- Biomarkers associated with COVID-19 disease progression.
- Authors: Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T
- Issue date: 2020 Sep